^
Association details:
Biomarker:LRRC3B hypomethylation
Cancer:Non Small Cell Lung Cancer
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

Published date:
01/24/2023
Excerpt:
Furthermore, responders to anti-PD1 immunotherapy showed lower methylation levels (Figure 12C), and in different silencing score groups (high vs low), the patients exhibited significant differences in immune response (Non-response vs. response) (Figures 12D, p = 0.003). These data suggest that DNA hypomethylation of LRRC3B could be used to predict anti-PD-1 treatment outcomes in NSCLC and BRCA.
DOI:
10.3389/fimmu.2023.959868